8-K: Inogen Reports Strong Q4 and Full Year 2024 Financial Results, Announces Yuwell Collaboration

Inogen announces a 5.5% increase in Q4 revenue and a 6.4% increase in full-year revenue for 2024, driven by strong business-to-business sales and strategic initiatives.

Summary

• Inogen reported a 5.5% increase in revenue for the fourth quarter of 2024, reaching $80.1 million, compared to $75.9 million in the same period of 2023.
• The increase was primarily driven by higher demand and new customers in international and domestic business-to-business sales.
• Full-year 2024 revenue increased by 6.4% to $335.7 million, up from $315.7 million in 2023.
• The company's gross margin improved to 45.3% in Q4 2024 from 37.1% in Q4 2023, and to 46.1% for the full year 2024 from 40.1% in 2023.
• Inogen's operating loss improved to $11.4 million in Q4 2024 from $29.0 million in Q4 2023, and to $42.5 million for the full year 2024 from $109.4 million in 2023.
• GAAP net loss for Q4 2024 was $9.8 million, compared to $26.6 million in Q4 2023, and for the full year 2024 was $35.9 million, compared to $102.4 million in 2023.
• Adjusted EBITDA was negative $3.6 million in Q4 2024, an improvement from negative $17.3 million in Q4 2023, and negative $9.5 million for the full year 2024 compared to negative $37.8 million for the full year 2023.
• As of December 31, 2024, Inogen had $117.4 million in cash, cash equivalents, and restricted cash, with no debt outstanding.
• Inogen expects revenue for the first quarter of 2025 to be in the range of $79 million to $81 million, representing a 1% to 4% growth.
• For the full year 2025, the company anticipates revenue between $352 million and $355 million, reflecting a 5% to 6% growth.
• In January 2025, Inogen entered into a strategic collaboration with Yuwell, with Yuwell investing approximately $27.2 million for a 9.9% stake in Inogen.

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, improved profitability metrics, and a strategic collaboration, but tempered by ongoing losses and market competition.

Positives

• Revenue growth in both Q4 and full-year 2024, driven by business-to-business sales.
• Improved gross margin due to lower raw material costs and operational efficiencies.
• Significant reduction in operating loss and net loss compared to the previous year.
• Strong cash position with $117.4 million and no debt.
• Strategic collaboration with Yuwell to expand product portfolio and global reach.

Negatives

• Lower direct-to-consumer sales and rental revenue, although offset by B2B growth.
• Negative adjusted EBITDA, although significantly improved year-over-year.
• Expected gross margin decrease in 2025 due to channel mix shift and costs associated with new product introductions.

Risks

• Market acceptance of new products, including Simeox.
• Competition in the respiratory products market.
• Risks associated with international operations.
• Potential impact of channel mix shift on gross margin.
• Uncertainties related to the collaboration with Yuwell.

Future Outlook

Inogen expects revenue in the range of $79 million to $81 million for the first quarter of 2025 and $352 million to $355 million for the full year 2025; gross margin is expected to be in the range of 43% to 45% for the full year 2025.

Management Comments

• 2024 was a stellar year for Inogen.
• With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability.
• With our leading portfolio of innovative respiratory care products, the pending introduction of Simeox in the U.S. and our recently announced collaboration with Yuwell, we believe we are well positioned to drive future growth, profitability and sustained success.

Industry Context

The respiratory care market is competitive, with companies like ResMed and Philips Respironics also offering homecare solutions; Inogen's collaboration with Yuwell, a major player in the Chinese market, could provide a significant advantage in expanding its global reach.

Comparison to Industry Standards

• ResMed, a leading competitor in the respiratory device market, reported revenue growth of 11% in its most recent quarter, indicating a strong overall market demand.
• Philips Respironics, another major player, has faced challenges due to product recalls, potentially creating opportunities for Inogen to gain market share.
• Inogen's gross margin of 46.1% is comparable to industry averages for medical device companies, but there is room for improvement to reach the levels of more profitable peers.

Related Party Transactions

• The company entered into a Securities Purchase Agreement with Yuwell (Hong Kong) Holdings Limited, a wholly-owned subsidiary of Yuwell, pursuant to which the subsidiary agreed to purchase 2,626,425 shares of the Company's common stock, par value $0.001 per share, for an aggregate purchase price of approximately $27.2 million.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved profitability.
• Employees may benefit from the company's growth and strategic initiatives.
• Customers will have access to a broader range of respiratory products through the Yuwell collaboration.
• Suppliers may see increased demand for raw materials and components.

Next Steps

• Inogen plans to introduce Simeox in the U.S.
• The company will continue to develop its collaboration with Yuwell.
• Inogen will host a conference call on February 25, 2025, to discuss the results.

Key Dates